Hhlr Advisors LTD. Buys Shares of 4,974,041 Gossamer Bio, Inc. $GOSS

Hhlr Advisors LTD. bought a new stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 4,974,041 shares of the company’s stock, valued at approximately $819,000. Hhlr Advisors LTD. owned about 2.12% of Gossamer Bio at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GOSS. Legal & General Group Plc acquired a new stake in Gossamer Bio in the second quarter valued at $26,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio during the 2nd quarter worth $27,000. Soltis Investment Advisors LLC acquired a new position in Gossamer Bio during the 4th quarter worth $31,000. MMA Asset Management LLC bought a new stake in shares of Gossamer Bio in the 4th quarter worth about $31,000. Finally, Beacon Pointe Advisors LLC bought a new stake in shares of Gossamer Bio in the 4th quarter worth about $34,000. Institutional investors own 81.23% of the company’s stock.

Analysts Set New Price Targets

GOSS has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gossamer Bio in a research report on Friday, August 14th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a report on Monday, July 27th. Finally, Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price objective on the stock in a research note on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.20.

Gossamer Bio Price Performance

Gossamer Bio stock opened at $0.17 on Thursday. Gossamer Bio, Inc. has a 12 month low of $0.11 and a 12 month high of $3.87. The company has a fifty day moving average price of $0.17 and a two-hundred day moving average price of $0.43. The company has a market cap of $40.81 million, a PE ratio of -0.25 and a beta of 2.04.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $9.24 million for the quarter, compared to analyst estimates of $3.63 million. Equities research analysts anticipate that Gossamer Bio, Inc. will post -0.56 earnings per share for the current year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.